Researchers at QPS Clinical Services GmbH and Universitat de Barcelona have divulged dual bifunctional epoxide hydrolase 2 (EPHX2; sEH) and glutaminyl-peptide cyclotransferase-like protein (QPCTL; IsoQC) inhibitors reported to be useful for the treatment of Alzheimer’s disease.

The Methodist Hospital System has identified triphenyl phosphonium compounds targeting mitochondria reported to be useful for the treatment of cancer.

The University of Texas System has synthesized mitogen-activated protein kinase 1 (MAPK1; ERK2) inhibitors reported to be useful for the treatment of cancer.

Vesper Bio ApS has disclosed sortilin (NT3; Gp95) antagonists reported to be useful for the treatment of neurodegeneration, cancer, pain, diabetes, diabetic retinopathy, glaucoma, hearing loss and cardiovascular disorders, among others.

Petragen Inc. has described ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer, gingivitis, musculoskeletal and connective disorders, hematological diseases, bone, cardiovascular, immunological and neurological disorders, among others.

Bash Biotech Inc. has divulged compounds reported to be useful for the treatment of lung cancer.

Synnovation Therapeutics Inc. has identified Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.

Uereka Biosciences Inc. has synthesized mitogen-activated protein kinase kinase kinase 13 (MAP3K13; LZK) inhibitors reported to be useful for the treatment of cancer.

Tohoku University has disclosed 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of viral infections and inflammatory disorders.

Haihe Biopharma Co. Ltd. has described androgen receptor antagonists reported to be useful for the treatment of acne, androgenic alopecia, breast and prostate cancer, benign prostatic hyperplasia, hidradenitis suppurativa, hirsutism and prostatitis.